Literature DB >> 30508502

Molecular types of Cryptococcus species isolated from patients with cryptococcal meningitis in a Brazilian tertiary care hospital.

Fernanda Wirth1, Maria Isabel Azevedo1, Luciano Z Goldani2.   

Abstract

There are limited data on the molecular epidemiology of cryptococcosis in Brazil. Here, we report on the identification of the molecular pattern of the Cryptococcus species that caused meningitis in patients admitted in a Brazilian reference tertiary care hospital, and review the published studies addressing the molecular epidemiology of Cryptococcus in Brazil. Our study has shown the predominance of molecular type VNII in HIV-infected patients with cryptococcal meningoencephalitis. Molecular types VNII and VGII were occasionally detected in HIV-infected and non-infected patients with meningoencephalitis. In contrast, previous studies have shown that several regions exhibited a high prevalence of the VNI molecular type and sporadic cases of the VNII and VGII molecular types in patients with cryptococcosis in Brazil. Additional studies including VNII isolates will contribute to understanding the epidemiology and phylogenetic relationship of these genotype compared to the other ones. So far, no clear correlation has been established between genotypes, antifungal susceptibility for Cryptococcus and clinical outcome in cryptococcosis.
Copyright © 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Brazil; Cryptococcus; Epidemiology; Genotypes; Molecular types

Mesh:

Year:  2018        PMID: 30508502      PMCID: PMC9425640          DOI: 10.1016/j.bjid.2018.11.002

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   3.257


Cryptococcosis is a systemic mycosis primarily caused by Cryptococcus neoformans species complex. The C. neoformans complex includes the molecular types VNI, VNII, VNB, VNIII, and VNIV, and the C. gattii species complex, which includes the molecular types VGI, VGII, VGIII, and VGIV.1, 2 Members of the C. neoformans species complex are responsible for most cases of cryptococcosis associated with AIDS. Using genotyping techniques four major molecular types can be identified VNI, VNII, VNB, VNIV, in addition to the AD hybrid. VNI and VNII have a worldwide distribution. In terms of serotypes, three varieties are recognized: C. neoformans var. grubii, serotype A, C. neoformans var. neoformans, serotype D, C. neoformans var. gattii, serotypes B and C, and the hybrid serotype AD.4, 5, 6 Meningitis is the most serious infectious due to Cryptococcus sp. The human immunodeficiency virus (HIV)/AIDS pandemic increased the population of immunosupressed and susceptible individuals and brought an increase in C. neoformans infection rates, but the increasing number of people living with any other immunodeficiency, including transplant and cancer patients, represents a growing population at risk for cryptococcosis.7, 8 The recent availability of DNA fingerprinting techniques extended our knowledge about C. neoformans epidemiology over the past years. Naturally, the randomized amplified polymorphic DNA, PCR-fingerprinting, restriction fragment length polymorphism, karyotyping, allele sequencing, and multilocus enzyme electrophoresis helped us to answer several questions. PCR fingerprinting technique has been used as the major typing technique in the ongoing global molecular epidemiologic survey of C. neoformans, dividing >400 clinical and environmental isolates into eight major molecular types: VNI (var. grubii, serotype A), VNII (var. grubii, serotype A), VNIII (serotype AD), VNIV (var. neoformans, serotype D), VGI, VGII, VGIII, and VGIV (var. gattii, serotypes B and C). No correlation between serotype and molecular type has been found for C. neoformans var. gattii. The molecular types were recently confirmed by RFLP analysis of the orotidine monophosphate pyrophosphorylase (URA5) gene and the phospholipase (PLB1) gene.9, 10, 11, 12, 13 Currently, there are limited data on the molecular epidemiology of cryptococcosis in Brazil. Here, we report on the identification of the molecular pattern of the Cryptococcus species that caused meningitis in patients admitted in a reference Brazilian tertiary care hospital, and review the published studies addressing the molecular epidemiology of Cryptococcus in Brazil. Cryptococcus sp. was isolated from the cerebrospinal fluid of patients with meningoencephalitis admitted at Hospital de Clinicas de Porto Alegre, 700-bed tertiary Brazilian reference hospital, from January 2014 to December 2015. Initially, C. neoformans and C. gattii were distinguished by a phenotypic method – CGB agar (cavanine glycine bromothymol blue agar). Detailed demographics, risk factors, treatment regimens and clinical outcome of the patients with meningeal cryptococcosis were evaluated from medical records. The study was approved by the local ethics committee. Cryptococcus complex reference strains were very kindly provided by Laboratory of Mycology (Pathogenic Fungi Collection), at Oswaldo Cruz Foundation (FIOCRUZ) – INI/FIOCRUZ in Brazil. The strains included were the following: WN = M 148 (VNI, serotype A), WM 626 (VNII, serotype A), WM 628 (VNIII, serotype AD), WM 629 (VNIV, serotype D), WM 179 (VGI, serotype B), WM 178 (VGII, serotype B), WM 161 (VGIII, serotype B) and WM 779 (VGIV, serotype C). The extraction of genomic DNA and RFLP analysis was performed according protocol using 2 primers: URA5 (5′ATGTCCTCCCAAGCCCTCGACTCCG3′) and SJ01 (5′ TTAAGACCTCTGAACACCGTACTC3′). RFLP patterns were assigned visually by comparing them to the patterns obtained from the standard-type strains (VNI-VNIV and VGI-VGIV).14, 15 Fifteen patients with cryptococcal meningoencephalitis were evaluated in the study (Table 1). The gene URA-5 RFLP showed that nine patients had VNII, serotype A, two patients VNI serotype A, and two had VGII, serotype B isolate from their CSF samples. Two patients presented a positive CSF cryptococcal polysaccharide antigen, and Cryptococcus could not be isolated from the CSF samples. As expected, the VNII, serotype A strains were isolated from patients with underlying immunossupressive disease. HIV positive was the most common condition, followed by kidney and liver transplant. Meningoencephalitis by C. gattii was diagnosed in two patients. One of them was immunocompetent and the other presented an immunosuppressive condition (HIV). Clinical isolates were highly susceptible to amphotericin B and fluconazole by microdilution method (data not shown). In Brazil, studies of the in vitro susceptibility of Cryptococcus spp. have shown that most isolates are susceptible to polyene antifungals, 5-flucytosine, and azoles.
Table 1

Cryptococcus species complex and genotype identification in the CSF samples from patients with cryptococcal meningitis.

Age/SexSpecies complexMolecular typeUnderlying diseaseTreatmentOutcome
154/MC. neoformansVNII, Serotype AKidney transplantLiposomal AmB + FCZDeath
26/MC. neoformansVNII, Serotype ALiver transplantAmB + 5-FCAlive
345/MNot availableNot availableHIV+AmB + FCZDeath
427/MC. neoformansVNII, Serotype BHIV+AmB + FCZAlive
565/MC. gattiiVGII, Serotype BImmunocompetentAmB + FCZ (VCZ)Death
633/FC. neoformansVNII, Serotype AKidney transplantAmB + FCZAlive
742/MC. neoformansVNII, Serotype AHIV+AmB + FCZAlive
855/MC. neoformansVNII, Serotype AHIV+AmB + FCZDeath
962/MC. neoformansVNII, Serotype AKidney transplantAmB + FCZAlive
1025/FC. neoformansVNII, Serotype AHIV+AmB + FCZAlive
1138/MC. neoformansVNI, Serotype AHIV+Lipid complex AmB + FCZAlive
1244/FC. neoformansVNII, Serotype AHIV+AmB + FCZAlive
1337/FC. neoformansVNI, Serotype AHIV+AmB + FCZDeath
1441/MC. gattiiVGII, Serotype BHIV+AmB + FCZDeath
1543/FNot availableNot availableHIV+AmB + FCZDeath

M, male; F, female; AmB, amphotericin B deoxycholate; FLZ, fluconazole; VCZ, voriconazole.

Cryptococcus species complex and genotype identification in the CSF samples from patients with cryptococcal meningitis. M, male; F, female; AmB, amphotericin B deoxycholate; FLZ, fluconazole; VCZ, voriconazole. Although we analyzed a small number of isolates, our study has shown the predominance of VNII Cryptococcus genotype in patients with meningoencephalitis. Previous studies have shown that the VNI molecular pattern is the most common pattern worldwide, whereas VNII was observed in 1%–16% of cases reported in South America, Africa, and Oceania.17, 2 C. gattii VGII was also observed in South America, North America, and Oceania. Table 2 describes the studies evaluating the Cryptococcus genotypes circulating in Brazil.18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 Several regions exhibited a high prevalence of the VNI molecular type and sporadic cases of the VNII and VGII molecular types in Brazil. The predominance of the VNI molecular type has been described in the States of São Paulo, Minas Gerais, Mato Grosso, Amazonas, PIauí, Rio Grande do Sul and Rio de Janeiro in Brazil.
Table 2

Studies addressing the prevalence of Cryptococcus molecular types in cryptococcosis in Brazil.

ReferenceLocation – statePredominant molecular typeOther molecular types
Wirth et al. (present case)Rio Grande do SulVNIIVNI, VGII
Nunes et al.18Mato Grosso do SulVNIVNI, VGII
Andrade-Silva et al.19Minas GeraisVNI
Aguiar et al.20Minas GeraisVNIVNI, VGI
Ferreira-Paim et al.21Minas GeraisVNI
Figueiredo et al.22São PauloVNIIVGII
Favalessa et al.23Mato GrossoVNIVGII
Freire et al.24AmazonasVNIVNII, VGII
Matos et al.25BahiaVNIVGII
da Silva et al.26AmazonasVNIVGII
Martins et al.27PiauíVNIVGII
Mora et al.28Minas GeraisVNIVGII
Souza et al.29GoiasVNIVGII
Triles et al.30RS, SP, MS, MG, BA PI, PE, RR, AMVNI, VGIIVNII, VNIII, VNIV, VGI, VGIII
Matsumoto et al.31São PauloVNIVNII
Igreja et al.32Rio de JaneiroVNI, VNIIVGI, VGII
Casali et al.33Rio Grande do SulVNIVGIII

RS, Rio Grande do Sul; SP, São Paulo; MS, Mato Grosso do Sul; MG, Minas Gerais; BA, Bahia; PI, Piauí; PE, Pernambuco; RR, Roraima; AM, Amazonas.

Studies addressing the prevalence of Cryptococcus molecular types in cryptococcosis in Brazil. RS, Rio Grande do Sul; SP, São Paulo; MS, Mato Grosso do Sul; MG, Minas Gerais; BA, Bahia; PI, Piauí; PE, Pernambuco; RR, Roraima; AM, Amazonas. Studies of molecular types of Cryptococcus contribute to the evaluation of the epidemiology, clinical manifestations, interventions and therapeutic approach for cryptococcosis. The presence of molecular type VNII was reported in all five continents, but little is known about its pathobiology, ecology, and antifungal susceptibility. Therefore, tools that are able to identify it are important to better understand how it is distributed in the environment, how it interacts with the host, and finally if it needs a different and more specific treatment to improve the patient outcome. Additional studies of VNII isolates will contribute to understanding the epidemiology and phylogenetic relationship of this genotype compared to the other ones, revealing if it represents a separate species in the C. neoformans species complex.

Conflicts of interest

The authors declare no conflicts of interest.
  32 in total

1.  Genotypes of Cryptococcus neoformans and Cryptococcus gattii as agents of endemic cryptococcosis in Teresina, Piauí (northeastern Brazil).

Authors:  Liline Maria Soares Martins; Bodo Wanke; Márcia dos Santos Lazéra; Luciana Trilles; Gláucia Gonçalves Barbosa; Regina Célia Lima de Macedo; Maria do Amparo Salmito Cavalcanti; Kelsen Dantas Eulálio; José Adail Fonseca de Castro; Adalberto Socorro da Silva; Fernando Ferraz do Nascimento; Viviane Alves Gouveia; Semiramis Jamil Hadad do Monte
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-09       Impact factor: 2.743

2.  Cryptococcal meningitis epidemiology: 17 years of experience in a State of the Brazilian Pantanal.

Authors:  Joslaine de Oliveira Nunes; Rosianne Assis de Sousa Tsujisaki; Maína de Oliveira Nunes; Gláucia Moreira Espíndola Lima; Anamaria Mello Miranda Paniago; Elenir Rose Jardim Cury Pontes; Marilene Rodrigues Chang
Journal:  Rev Soc Bras Med Trop       Date:  2018 Jul-Aug       Impact factor: 1.581

Review 3.  Epidemiology: surveillance of fungal infections.

Authors:  D Ellis; D Marriott; R A Hajjeh; D Warnock; W Meyer; R Barton
Journal:  Med Mycol       Date:  2000       Impact factor: 4.076

4.  A new genus, filobasidiella, the perfect state of Cryptococcus neoformans.

Authors:  K J Kwon-Chung
Journal:  Mycologia       Date:  1975 Nov-Dec       Impact factor: 2.696

5.  A new species of Filobasidiella, the sexual state of Cryptococcus neoformans B and C serotypes.

Authors:  K J Kwon-Chung
Journal:  Mycologia       Date:  1976 Jul-Aug       Impact factor: 2.696

6.  Genotyping, serotyping and determination of mating-type of Cryptococcus neoformans clinical isolates from São Paulo State, Brazil.

Authors:  Marcelo Teruyuki Matsumoto; Ana Marisa Fusco-Almeida; Lilian Cristiane Baeza; Márcia de Souza Carvalho Melhem; Maria José Soares Medes-Giannini
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2007 Jan-Feb       Impact factor: 1.846

7.  Characterization of clinical isolates of the Cryptococcus neoformans-Cryptococcus gattii species complex from the Amazonas State in Brazil.

Authors:  Babbyngttonn Khell Da Silva; Ana Karla Freire; Amaury Dos Santos Bentes; Ivanete De Lima Sampaio; Lucilaide Oliveira Santos; Mirlane Silva Dos Santos; João Vicente De Souza
Journal:  Rev Iberoam Micol       Date:  2011-06-02       Impact factor: 1.044

8.  Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates.

Authors:  S P Franzot; I F Salkin; A Casadevall
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Molecular epidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian city, Rio de Janeiro.

Authors:  R P Igreja; M Dos Santos Lazéra; B Wanke; M C Gutierrez Galhardo; S E Kidd; W Meyer
Journal:  Med Mycol       Date:  2004-06       Impact factor: 4.076

Review 10.  Global Molecular Epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An Atlas of the Molecular Types.

Authors:  Massimo Cogliati
Journal:  Scientifica (Cairo)       Date:  2013-01-09
View more
  6 in total

Review 1.  Cryptococcus spp. and Cryptococcosis: focusing on the infection in Brazil.

Authors:  Fabíolla Nacimento do Carmo; Juliana de Camargo Fenley; Maíra Terra Garcia; Rodnei Dennis Rossoni; Juliana Campos Junqueira; Patrícia Pimentel de Barros; Liliana Scorzoni
Journal:  Braz J Microbiol       Date:  2022-04-29       Impact factor: 2.214

2.  Transmission of cryptococcosis by liver transplantation: A case report and review of literature.

Authors:  Gustavo de Sousa Arantes Ferreira; Andre Luis Conde Watanabe; Natalia de Carvalho Trevizoli; Fernando Marcus Felippe Jorge; Carolina de Fatima Couto; Priscila Brizolla de Campos; Gabriel Oliveira Nunes Caja
Journal:  World J Hepatol       Date:  2020-05-27

Review 3.  Cryptococcus neoformans and Cryptococcus gattii Species Complexes in Latin America: A Map of Molecular Types, Genotypic Diversity, and Antifungal Susceptibility as Reported by the Latin American Cryptococcal Study Group.

Authors:  Carolina Firacative; Wieland Meyer; Elizabeth Castañeda
Journal:  J Fungi (Basel)       Date:  2021-04-09

4.  Mixed infection by Cryptococcus neoformans and Cryptococcus gattii and coinfection with paracoccidioidomycosis in PLHIV.

Authors:  Marcela de Faria Ferreira; Fabio Brito-Santos; Pedro Henrique Nascimento Theodoro; Marcos de Abreu Almeida; Marcia Dos Santos Lazera; Luciana Trilles
Journal:  Med Mycol Case Rep       Date:  2022-01-27

5.  Early clinical and microbiological predictors of outcome in hospitalized patients with cryptococcal meningitis.

Authors:  Lidiane de Oliveira; Marcia de Souza Carvalho Melhem; Renata Buccheri; Oscar José Chagas; José Ernesto Vidal; Fredi Alexander Diaz-Quijano
Journal:  BMC Infect Dis       Date:  2022-02-09       Impact factor: 3.090

6.  Clinical and microbiological characteristics of cryptococcosis at an university hospital in China from 2013 to 2017.

Authors:  Lan-Fang Fang; Piao-Piao Zhang; Jie Wang; Qing Yang; Ting-Ting Qu
Journal:  Braz J Infect Dis       Date:  2019-12-20       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.